Christina Bolch

Director of Engineering at CorInnova, Inc.

Role: Director of Engineering at Corinnova, Inc
Location: Houston, TX, US
LinkedIn followers: 500 followers

About Christina Bolch

Dr. Christina Bolch is an engineer with over 15 years of experience in cardiovascular device research and development. Christina joined the CorInnova team in 2007 as an R&D Engineering Intern, and continued to work with the company while working on her Bachelor of Science, Master of Engineering, and Doctor of Philosophy degrees in Biomedical Engineering at Texas A&M University. Prior to joining the team full time in 2012, Dr. Bolch collaborated with the Cardiac Rhythm Management division of Medtronic to model effects of pacemaker lead placement on contraction strain patterns from 20••••10.

Experience

Director of Engineering
Corinnova, Inc
Mar 2025 — Present · US

Education

Texas A&M University
Doctor of Philosophy (Ph.D.), Biomedical Engineering
2010 — 2012
Texas A&M University
Bachelor of Science (B.S.), Biomedical Engineering
2003 — 2007
Texas A&M University
Master of Engineering (M.Eng.), Biomedical Engineering
2008 — 2010

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@corinnova.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Corinnova, Inc

Medical Equipment Manufacturing · 20 employees · Houston, Texas, United States

Johnson & Johnson Innovation JLABS @ TMC, Houston. With a lead investment from the UK-based Wellcome Trust, a premier international medical foundation, CorInnova is developing a non-blood contacting cardiac assist device. CorInnova\'s device is a transformative biventricular device to treat acute heart failure. The technology will create a new paradigm for treatment. The device is designed to eliminate adverse events associated with existing cardiac assist technologies, and to expand eligible patients. The device may reverse the progression of HF, a blockbuster application. The device deploys minimally invasively into the pericardial sac in under 30 seconds, and has shown the ability to increase cardiac output by up to 50%. Addressable markets are up to $10 billion.

corinnova.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.